Exelixis Files IND Application for XL019, a Novel Anticancer Compound Targeting the JAK/STAT Signaling Pathway

30-May-2007 - Exelixis, Inc. announced that it has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration for XL019. The compound has shown to be a potent, selective and orally available small molecule inhibitor of the cytoplasmic tyrosine kinase JAK2, in preclinical ...

Exelixis Appoints Carl B. Feldbaum, President Emeritus of the Biotechnology Industry Organization, to Its Board of Directors

13-Feb-2007 - Exelixis, Inc. announced that Carl B. Feldbaum, president emeritus of the Biotechnology Industry Organization (BIO), has been appointed to the company's Board of Directors. Prior to retirement from BIO in 2005, he served as president of that organization which represents more than 1,000 ...

Exelixis and Bristol-Myers Squibb Sign New Collaboration Agreement to Discover and Develop Novel Oncology Compounds

20-Dec-2006 - Exelixis, Inc. and Bristol-Myers Squibb Company announced a worldwide collaboration to discover, develop and commercialize novel targeted therapies for the treatment of cancer. Under the collaboration, which will become effective upon antitrust clearance, Exelixis will deploy its drug discovery ...

Exelixis and Sankyo Sign Collaboration Agreement to Develop Novel Therapies for Cardiovascular Disease

22-Mar-2006 - Exelixis, Inc. and Sankyo Company (a wholly owned subsidiary of DAIICHI SANKYO COMPANY, LIMITED) announced a collaboration agreement to discover, develop and commercialize novel therapies targeted against the mineralocorticoid receptor (MR), a nuclear hormone receptor (NHR) implicated in a ...

Exelixis and Helsinn Sign Agreement for XL119 (becatecarin)

15-Jun-2005 - Exelixis, Inc. and Helsinn Healthcare S.A. reached an agreement for the development of XL119 (becatecarin). Under the terms of the agreement, Helsinn will pay Exelixis an upfront payment of $4 million and additional milestones up to $21 million. In addition, Helsinn will assume the cost of the ...

Exelixis and Genentech Collaborate on Novel Therapeutics for Cancer, Inflammation, and Tissue Growth and Repair

07-Jun-2005 - Exelixis, Inc. announced that it has signed a collaboration agreement with Genentech for the discovery and development of therapeutics to target cancer, inflammatory diseases, and tissue growth and repair. The collaboration combines the intellectual property and biological capabilities of both ...

Exelixis Amends Collaboration With GenOptera

05-Apr-2005 - Exelixis, Inc. announced that Exelixis, Bayer CropScience and GenOptera LLC have mutually agreed to amend their collaboration agreement by ending the research phase of the work as of March 31, 2005. GenOptera is a joint venture established by Exelixis and Bayer CropScience to facilitate the ...

Exelixis Publishes World's Most Comprehensive Collection of Functional Gene Knockouts in a Multicellular Organism

24-Feb-2004 - South San Francisco. Scientists at Exelixis, Inc. published two landmark articles describing the most complete functional genetic toolkit for studying a multicellular organism. The Exelixis collection includes specific disruptions in a majority of genes in the fruit fly, Drosophila melanogaster. ...

Exelixis and Dow Agrosciences Extend Research Collaboration

11-Aug-2003 - Exelixis, Inc. announces the extension of its mechanism of action research collaboration with Dow AgroSciences LLC. The one-year extension will enable the two companies to build on their substantial accomplishments in elucidating the mechanism of action of important herbicidal compounds based on ...

Exelixis Announces the Discovery of Two Proteins Involved in Alzheimer’s Disease

Discovery Could Lead to New Therapeutic Approaches to CNS Disorders

09-Jul-2002 - SOUTH SAN FRANCISCO, Calif. July 8, 2002 Scientists at Exelixis, Inc., working in collaboration with Pharmacia Corporation have discovered two proteins that play a role in the production of beta-amyloid, the main constituent of senile plaques associated with Alzheimer’s disease. aph-1 and pen-2 ...